MIST Overview

FDA Approval: Milestone Pharmaceuticals Inc. has received FDA approval for CARDAMYST nasal spray, the first treatment for paroxysmal supraventricular tachycardia (PSVT) in over 30 years, allowing patients to self-administer the medication outside of healthcare settings.

Condition Overview: PSVT affects over two million Americans, causing sudden episodes of rapid heart rate and associated symptoms like palpitations and shortness of breath, particularly among young individuals during vigorous activities.

Product Details: CARDAMYST is a rapid-acting calcium channel blocker designed to treat acute episodes of PSVT, expected to be available in retail pharmacies by the first quarter of 2026.

Stock Performance: Following the announcement, Milestone Pharmaceuticals' stock experienced fluctuations, trading at $2.41 after reaching a 52-week high of $3.06.

FDA Approval: Milestone Pharmaceuticals Inc. received FDA approval for CARDAMYST (etripamil) nasal spray, a treatment for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults.

Access to Treatment: The approval allows over two million Americans with PSVT to access a rapid-acting, self-administered treatment option outside of healthcare settings, enhancing their ability to manage episodes.

Product Availability: CARDAMYST is expected to be available in retail pharmacies starting in the first quarter of 2026.

Stock Performance: Following the announcement, MIST's stock closed at $2.41, a decline of 18.31%, but saw a slight recovery in after-hours trading to $2.46.